Press Release Archives - Page 7 of 22

Spectral Medical Provides Early February Tigris Trial Update

88 patients enrolled January being the highest enrollment month since the launch of Tigris TORONTO, Canada – February 5, 2024 – Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options...

Spectral Medical Provides January Tigris Trial Update

85 Patients Enrolled TORONTO, Canada – January 30, 2024 – Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today provided an update on the Company’s Tigris...

Spectral Medical Enrolls Patient 82 in Its Phase 3 FDA Tigris Septic Shock Trial

New patient enrollment sites accelerating screening activity Screening activity exceeding 100 patients per week Approaching interim enrollment target of 90 patients TORONTO, Canada – January 10, 2024 – Spectral Medical Inc. (“Spectral” or the “Company”) (TSX:...

Spectral Medical Provides Tigris Trial Update

81 patients enrolled TORONTO, Canada – December 14, 2023 – Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today provided an update on the Company’s...

Spectral Medical Provides November Tigris Trial Update

79 patients enrolled TORONTO, Canada – December 4, 2023 – Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today provided an update for the month of...

Spectral Medical Announces CFO Departure

TORONTO, Canada – December 1, 2023 – Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced that Blair McInnis has provided notice of his...

« Older Entries

Next Entries »

EAA™ and PMX are licensed and available for use in Canada. PMX is not approved for clinical use in the USA, and is currently undergoing the PMA (Premarket approval) process. EAA™ is FDA cleared for use in the USA. The information presented herein is region specific. Please contact Spectral Medical Inc.to obtain appropriate product information for your country.